Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

BACKGROUND. Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qualitative changes in effector T cells and prolonged preservation of endogenous insul...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Invest
Main Authors: Rigby, Mark R., Harris, Kristina M., Pinckney, Ashley, DiMeglio, Linda A., Rendell, Marc S., Felner, Eric I., Dostou, Jean M., Gitelman, Stephen E., Griffin, Kurt J., Tsalikian, Eva, Gottlieb, Peter A., Greenbaum, Carla J., Sherry, Nicole A., Moore, Wayne V., Monzavi, Roshanak, Willi, Steven M., Raskin, Philip, Keyes-Elstein, Lynette, Long, S. Alice, Kanaparthi, Sai, Lim, Noha, Phippard, Deborah, Soppe, Carol L., Fitzgibbon, Margret L., McNamara, James, Nepom, Gerald T., Ehlers, Mario R.
Format: Artigo
Sprog:Inglês
Udgivet: American Society for Clinical Investigation 2015
Fag:
Clinical Medicine
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623571/
https://ncbi.nlm.nih.gov/pubmed/26193635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI81722
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker